Breaking News
January 17, 2019 - Educational videos in clinical settings increase HPV vaccination rates among adolescents
January 17, 2019 - Better understanding of aggressive brain tumour
January 17, 2019 - Why is life expectancy in the U.S. going down? A Q&A
January 17, 2019 - The Electronics Industry Sees Money In Your Health
January 17, 2019 - Hypertension drug may improve effectiveness of ovarian cancer treatment
January 17, 2019 - Scientists reveal key mechanism in worms that controls cell’s response to stress
January 17, 2019 - How Patch Clamp Technology Can Benefit Ion Channel Research
January 16, 2019 - Researchers cultivate organoids that perfectly mimic blood vessels
January 16, 2019 - Sound Pharmaceuticals Advances Phase 2 Hearing Loss Clinical Trial in Cystic Fibrosis
January 16, 2019 - Unraveling the genetic causes of skin cancer
January 16, 2019 - Higher percentages of saturated fat in low-carb diets may not harm cholesterol levels, new analysis suggests
January 16, 2019 - Using bottled or tap water impacts health benefits of green tea
January 16, 2019 - Best trained alert dogs have potential to improve Type 1 diabetes patients’ quality of life
January 16, 2019 - States with lower incidence of melanoma have higher mortality rates
January 16, 2019 - Pollution on the London Underground found to be dangerously high
January 16, 2019 - Breast cancer cells in mice coaxed to turn into harmless fat cells
January 16, 2019 - Study connects the genetic background of autistic spectrum disorders with stem cell dysfunction
January 16, 2019 - When activated, ‘social’ brain circuits inhibit feeding behavior in mice | News Center
January 16, 2019 - How Exercise May Help Keep Our Memory Sharp
January 16, 2019 - Researchers identify a key regulator that stops excessive inflammation
January 16, 2019 - TGF-beta signaling pathway in uterine cells protects against cancer
January 16, 2019 - MD Anderson Cancer Center collaborates with Dragonfly for new immunotherapy drug clinical trials
January 16, 2019 - Drug Repurposing May Provide More Psychiatric Tx Options
January 16, 2019 - A new brain imaging study challenges the dominant theoretical model of autism spectrum disorders
January 16, 2019 - GoFundMe CEO: ‘Gigantic Gaps’ In Health System Showing Up In Crowdfunding
January 16, 2019 - Induced neuronal cells derived from fibroblasts are similar to neurons in the brain
January 16, 2019 - New study finds link between childhood abuse and suicide in later life
January 16, 2019 - Lifestyle and health factors that are good for the heart can also prevent diabetes
January 16, 2019 - Scientists take another step in understanding bacteria that cause Salmonella epidemic
January 16, 2019 - Look to Your Aunts, Uncles and Parents for Clues to Your Longevity
January 16, 2019 - Study finds ADHD drugs are unlikely to cause cardiac damage in children who take them
January 16, 2019 - Call The Midwife! (If The Doctor Doesn’t Object)
January 16, 2019 - Changes in hippocampal structural connectivity differentiate responders of electroconvulsive therapy
January 16, 2019 - Study sheds light on the deadly venom of Mojave rattlesnakes
January 16, 2019 - University of Nebraska to develop new drugs that prevent and counteract effects of radiation exposure
January 16, 2019 - Sugar-based stent makes precarious sewing process easier
January 16, 2019 - FDA-approved drug hampers cancer metastasis in animal model, shows study
January 16, 2019 - Low-level cannabis use can change the adolescent brain
January 16, 2019 - MTC in Rouen acquires Robocath’s R-One robot for future healthcare practitioner training
January 16, 2019 - OSSIO granted FDA 510(k) market clearance for OSSIOfiber Bone Pin Family
January 16, 2019 - Childhood body composition may play a role in future respiratory health
January 16, 2019 - Outdated commissioning methods are failing mental health services in the UK, reveals report
January 16, 2019 - Unconventional immune cells trigger disturbed cytokine production in human spondyloarthritis
January 16, 2019 - Patients Turn To GoFundMe When Money And Hope Run Out
January 16, 2019 - Researchers develop novel viral identification method
January 16, 2019 - Study proposes improvements in pharmacological study of cognitive function enhancers in schizophrenia
January 16, 2019 - Study points to potential new biomarker and drug target for amyotrophic lateral sclerosis
January 16, 2019 - Differences in geographic origin of genes may affect mitochondrial function
January 16, 2019 - Study analyzes vaccine-preventable infections in children who receive solid organ transplants
January 16, 2019 - MiRagen Announces New Clinical Data in Patients With Three Different Types of Blood Cancers Treated With Cobomarsen
January 16, 2019 - Scientists uncover why knee joint injury leads to osteoarthritis
January 16, 2019 - Salk team uses new model to study health effects of AMP-activated protein kinase
January 16, 2019 - Research reveals novel approach to suppressing chemotherapy-induced tumor growth
January 16, 2019 - Researchers reveal how fasting leads to better overall health
January 16, 2019 - Deprivation and neglect in early childhood have impact on cognitive functioning in adolescence, shows study
January 16, 2019 - Training Students to use Imaging Techniques: NMR and EPR
January 16, 2019 - Nerve transfer surgery restores arm movement in children with acute flaccid myelitis
January 16, 2019 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
January 16, 2019 - DNA vaccine reduces both toxic proteins linked to Alzheimer’s
January 16, 2019 - Even in the U.S., poor women often can't afford tampons, pads
January 16, 2019 - One time use of Marijuana could affect teen brains finds study
January 16, 2019 - Persistent Opioid Use High in Head, Neck Cancer Patients
January 16, 2019 - Questions to ask your doctor about post pregnancy care: MedlinePlus Medical Encyclopedia
January 16, 2019 - Neurons with good housekeeping are protected from Alzheimer’s
January 16, 2019 - Is mindfulness worthy of all the hype?
January 16, 2019 - Physical Activity, Any Type or Amount, Cuts Health Risk from Sitting
January 16, 2019 - New understanding in the evolution of human feet
January 15, 2019 - AHA: New Cholesterol Guidelines Put Ethnicity in the Spotlight
January 15, 2019 - Different brain areas linked to smoking and drinking
January 15, 2019 - Henry Marsh shares insights into neurosurgery and more at Dean’s Lecture Series
January 15, 2019 - Want to Live Longer? For Just 30 Minutes a Day, Do Anything Else But Sit
January 15, 2019 - The Current issue of “The view from here” is concerned with Targets
January 15, 2019 - Plain packaging sparked tobacco price rises, new study finds
January 15, 2019 - Sedentary lifestyles can be unhealthy, physical activity can lower risk
January 15, 2019 - Gut microbiome may help prevent development of cow’s milk allergy
January 15, 2019 - Lesbian, gay and bisexual individuals more likely to suffer severe substance use disorders
January 15, 2019 - New England Journal of Medicine Publishes Positive Results of the Pivotal Trial of Cablivi (caplacizumab) for Rare Blood Clotting Disorder
January 15, 2019 - Levels of inflammatory marker (CRP) linked to housing type and tenure
January 15, 2019 - Three gifts I’m glad I gave myself in 2018
January 15, 2019 - Columbia’s Pediatrics Department Names New Vice Chairs, Expands Leadership
Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

Immunotherapy with pembrolizumab extends survival in metastatic or recurrent head and neck cancer

image_pdfDownload PDFimage_print

Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasized, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich.

The current standard treatment for metastatic or recurrent head and neck cancer is platinum-based chemotherapy (5-fluorouracil (5-FU) with cisplatin or carboplatin) plus the EGFR inhibitor cetuximab. Around 35% of patients respond to treatment, which leads to a median survival of just over ten months.

The phase III KEYNOTE-048 study examined whether the anti-PD-1 monoclonal antibody pembrolizumab could prolong survival and slow cancer growth compared to standard treatment. KEYNOTE-048 enrolled patients with head and neck cancer who had not received prior chemotherapy or biologic therapy for recurrent or metastatic disease. Patients were randomly allocated in a 1:1:1 ratio to: 1) standard treatment with platinum-based chemotherapy (5-FU with cisplatin or carboplatin) and cetuximab (the control group); 2) pembrolizumab alone; or 3) a novel combination of pembrolizumab and platinum-based chemotherapy.

At ESMO 2018 researchers presented results on pembrolizumab alone compared to standard treatment in patients expressing PD-L1, a marker of immune activity, and on the novel combination compared to standard treatment in all patients regardless of PD-L1 expression.

In the first comparison, 301 patients received pembrolizumab and 300 patients had standard treatment, with median follow up of 11.7 and 10.7 months, respectively. The patient demographics and disease characteristics were similar between the treatment arms.

In patients with tumor and/or surrounding cells expressing PD-L1 (combined positive score [CPS] >20), overall survival was significantly longer with pembrolizumab (14.9 months) than standard treatment (10.7 months, hazard ratio [HR] 0.61, p=0.0007). Some 23.3% responded to pembrolizumab and 36.1% responded to standard treatment. Median response duration was longer with pembrolizumab (20.9 months) than standard therapy (4.5 months). There was no difference in progression-free survival between groups (HR 0.99, 95% confidence interval [CI] 0.75-1.29).

“Patients with PD-L1 expression live longer when they have initial treatment with pembrolizumab,” said first author Prof Barbara Burtness, Yale School of Medicine and Co-Director, Development Therapeutics Research Program, Yale Cancer Center, New Haven, US.

The results were similar in patients with a lower cut point of PD-L1 expression (CPS >1). Overall survival was significantly longer with pembrolizumab (12.3 months) compared to standard care (10.3 months, HR 0.78, p=0.0086). Some 19.1% on pembrolizumab responded to treatment compared to 34.9% on standard chemotherapy. Median response duration was longer with pembrolizumab (20.9 months) than standard chemotherapy (4.5 months). There was no difference in progression-free survival between groups (HR 1.16, 95% CI 0.75-1.29).

In the second comparison, 281 patients received the novel combination of pembrolizumab and platinum-based chemotherapy and 278 received standard treatment, with median follow-up of 13.0 and 10.7 months, respectively. (2) Patient demographics and disease characteristics were similar between treatment arms. Overall survival was prolonged with the combination (13.0 months) versus standard care (10.7 months, HR 0.77, p=0.0034). Response rates were 35.6% for the pembrolizumab combination and 36.3% for standard treatment. There was no difference in progression-free survival between groups (HR 0.92, 95% CI 0.77-1.10).

Side effects in the three treatment groups were as expected. Pembrolizumab alone was less toxic than standard treatment. Pembrolizumab combined with chemotherapy and standard treatment had similar toxicity.

Burtness noted that compared to standard care, pembrolizumab alone had a lower response rate and numerically shorter progression-free survival, but significantly longer overall survival. She said: “Pembrolizumab appears to prolong life even when the cancer continues to grow, suggesting that it should be a first line therapy in recurrent and metastatic head and neck cancer. Whether pembrolizumab is given alone or with chemotherapy may depend on PD-L1 expression and we are conducting analyses to answer this question.”

Commenting on the findings for ESMO, Dr Tanguy Seiwert, Head and Neck Cancer Programme Director, and Assistant Professor of Medicine at the University of Chicago Medicine, Chicago, US, said: “This is the first study to show superior overall survival over the decade-old standard of care, platinum-based chemotherapy and cetuximab, and establishes PD-L1 CPS as a valid marker for head and neck cancer that should be routinely measured in these patients.”

But he added: “The challenge is that treatment benefit is not equally distributed but depends on a biomarker. Hence, PD-L1 CPS expression will likely inform our choice between the two new options – pembrolizumab alone, with a favourable side effect profile, and pembrolizumab combined with chemotherapy, which may be used in a larger group of patients. Higher PD-L1 expression is associated with more benefit but the exact cut points have to be determined, and individual patient characteristics will play an important role as well. Separate analyses are needed in patients who have tumors with low or absent PD-L1 expression, where there is potentially less benefit.”

Regarding the need for further research, Seiwert said: “The usefulness of other biomarkers to select patients for treatment, such as tumour mutational burden, should also be examined.”

Source:

http://esmo.org/Press-Office/Press-Releases/KEYNOTE048-head-neck-cancer-immunotherapy-Burtness

About author

Related Articles